Antifolates show promise against NSCLC subtype
Monday, November 14, 2011 - 04:31
in Health & Medicine
Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.